PIK3CG and ovarian carcinoma: MSC2363318A is a CNS penetrant, ATP competitive inhibitor of p70S6K, AKT1, and AKT3 inhibitor which has shown activity in breast, pancreatic, and ovarian cancer cell lines in preclinical studies and was first evaluated in phase I study in patients with advanced malignancies with PI3K/AKT/PTEN pathway alterations, but the best response was stable disease [214].